Pigmentary glaucoma: Symptoms, cause, and treatment
Treatments, Patient Characteristics Affect Uveal Melanoma Survival
A new study identified the elements that could determine the overall survival of patients with the metastatic eye tumor, uveal melanoma.
Factors such as female sex, metastatsis type, better baseline performance status and laboratory measurements can all impact uveal melanoma outcomes, recent research showed.
Patients with metastatic uveal melanoma (UM) experienced improved survival outcomes if treated with immune checkpoint inhibitors (ICIs, a type of immunotherapy that assists the immune system find and fight cancer), including anti-CTLA-4 and anti-PD-1 therapies, according to the findings of a new study.
Factors such as female sex, extrahepatic-only metastases (secondary malignant growths not in the liver), better baseline performance status on the Eastern Cooperative Oncology Group (ECOG) Performance Status Scale, laboratory measurements and metastasis location all "contributed to a more than 2-fold reduction in death risk," according to the authors of the study, published in the journal Cancer.
Uveal melanoma, the authors of the study noted, is the most common intraocular (within the eyeball) cancer among adult patients.
"Although treatment modalities for the primary tumor have excellent local control (>95%), roughly 27% to 34% of patients develop distant metastases within 10 years," the authors wrote. "Once clinical metastases are detected, median overall survival is usually less than 1 year."
"Uveal melanoma, sometimes called ocular melanoma or eye melanoma, is the most common eye tumor in adults, but it is a very rare subtype of melanoma, only affecting about six per million people," Dr. Marlana Orloff, an associate professor of medicine at Thomas Jefferson University Hospital in Philadelphia, explained during CURE®'s Educated Patient Sound Bites on metastatic uveal melanoma in June.
"We don't know what causes eye melanoma," Orloff said. "Unlike skin melanoma, we don't think UV (ultraviolet radiation) is the cause. However, risk factors are similar to eye melanoma in being fair skinned and having light eyes. For most patients with eye melanoma, it is a spontaneous disorder, meaning it isn't necessarily inherited. But in about 1% to 2% of all eye melanoma, they can inherit a genetic mutation called BAP1 syndrome."
The study was a retrospective review of 89 patients with metastatic UM, 71 at Yale New Haven Health in the initial cohort and 18 in the validation cohort at Memorial Sloan Kettering Cancer Center in New York.
The cohort of Yale patients were treated between March 2007 and November 2021, with a median follow-up of 19.8 months and a median overall survival (OS, the time following treatment that a patient is still alive) of 21.8 months. Development of hepatic metastases and a low ECOG score were both associated with worse survival outcomes. Patients in the validation cohort were treated via the ocular oncology service at Memorial Sloan Kettering between February 2005 and June 2022.
The Food and Drug Administration (FDA) approved Kimmtrak (tebentafusp-tebn) for the treatment of patients with unresectable or metastatic uveal melanoma who are HLA-A*02:01 positive.
"Kimmtrak is a newer type of immunotherapy, also called a T-cell redirector, that acts like a magnet that combines your own immune system, your T cell, and drags it over to a target on the cancer, something called gp100 (glycoprotein 100), and kind of forces them to engage, hopefully allowing the immune system to kill the cancer," Orloff explained to CURE®.
But, as the authors of the recent Cancer study explained, only about half of the population is HLA-A*02:01-positive.
"Therefore, there is still a critical need to identify alternative treatment options for patients who may not be eligible to receive (Kimmtrak)," the authors wrote.
Kimmtrak is first immune therapy agent to show significant overall survival impact in a randomized trial setting, with a median OS of 21.7 months versus a median OS of 16 months in a phase 3 trial, the Cancer authors wrote, nothing that "this has renewed interest in immune therapy as a therapeutic option for metastatic uveal melanoma."
Participants in the Cancer study who received treatment with any ICI had a median OS of 29.2 months.
"Nevertheless, our data, along with those from the subgroup analysis in the (Kimmtrak) study, suggest that a large randomized controlled trial comparing anti–CTLA‐4 therapy to (Kimmtrak), ideally to patients with the HLA‐A*02:01 haplotype, may be warranted," they wrote.
For more news on cancer updates, research and education, don't forget to subscribe to CURE®'s newsletters here.
Shining Bright: Uveal Melanoma Treatment Market Set To Soar With A Stunning 10-Year Valuation And Impressive 5.5% CAGR
FMI presents a comprehensive analysis of the Uveal melanoma Treatment Market, based on the most recent insights and statistics from the world's largest pharmaceutical and healthcare device manufacturers.
The uveal melanoma treatment market is assessed to get a valuation of US$ 1.4 Billion out of 2023 and is assessed to ascend to US$ 2.4 Billion by 2033. The market is expected to develop at a CAGR of 5.5% during the conjecture time frame.
FMI provides insights into market data on over 5000+ drugs from over 100 countries, which aids research on the current and upcoming market scenario for the Uveal melanoma Treatment market. Our healthcare experts track the data of established players as well as new entrants in the medical industry to provide unbiased analysis for a sound and financial decision.
Attain a visually compelling report with accompanying graphs and charts.Get a Sample Copy of the Report @ https://www.Futuremarketinsights.Com/reports/sample/rep-gb-13010
Over the past decade, the healthcare sector has been expanding remarkably, following the advent of artificial Intelligence and the Internet of Things integrated medical devices. Advancement in technology has created impressive scope within the medical sector for diagnostics and therapeutics.
The report offers extensive data sets validating key trends impacting growth in the Uveal melanoma Treatment market. It offers insights into strategies adopted by the key players rise and addresses the concerns that will challenge the growth of Uveal melanoma Treatment market. With our extensive research and information about the past, current and future market scenario, the Uveal melanoma Treatment market report will help and identify the concerns, for a smooth sail of the small & medium as well as large enterprises.
Critical Questions Answered in the Report
Uveal melanoma Treatment Market: Segmentation
Based on diagnostic tests :
Based on therapy type :
Based on Location Type :
Based on Eye exams :
Based on end user :
Comprehensive analysis of the regional markets offers exclusive insights on the market performance across geographies along with relevant graphs, figures, and a list of tables.
Turn heads and inspire awe with a meticulously customized report. @ https://www.Futuremarketinsights.Com/customization-available/rep-gb-13010
Competitive Analysis
By Prominent Market Players
With an extensive SWOT analysis, the FMI's study presents the strengths, weaknesses, growth prospects and challenges of each player. The report also includes important data including the sales strategy, pricing strategy, and marketing strategy adopted by these players in the Uveal melanoma Treatment market
Explore Wide-ranging Coverage of FMI's Healthcare Landscape:
Amniotic Membranes Market: The global amniotic membranes market size is likely to touch a valuation of around US$ 1.4 Bn in 2022. Further, with rising adoption of amniotic membranes for various purposes in ophthalmology, the total sales of amniotic membranes are slated to grow at an impressive CAGR of 9.0% between 2022 and 2028, totalling over US$ 2.3 Bn by the end of 2028.
Digital Radiography Detectors Market: The digital radiography detectors market is valued at US$ 2.13 Bn in 2022. The market is advancing at an average pace with a CAGR of 6.1% through 2026 to reach a valuation of US$ 2.7 Bn. The worldwide market for digital radiography detectors is highly concentrated, with large competitors such as Varex Imaging Corporation and Trixell accounting for about 47% of the market share.
Sepsis Diagnostics Market: The global sepsis diagnostics market is expected to record a CAGR of 8.1% between 2023 and 2033. In 2023, the market is estimated to be valued at US$ 561.2 million. The valuation is expected to cross US$ 1.2 billion by 2033
About Future Market Insights (FMI)
Future Market Insights, Inc. (ESOMAR certified, Stevie Award – recipient market research organization and a member of Greater New York Chamber of Commerce) provides in-depth insights into governing factors elevating the demand in the market. It discloses opportunities that will favor the market growth in various segments on the basis of Source, Application, Sales Channel and End Use over the next 10-years.
Contact Us:
Future Market Insights Inc.Christiana Corporate, 200 Continental Drive,Suite 401, Newark, Delaware – 19713, USAT: +1-845-579-5705For Sales Enquiries: sales@futuremarketinsights.ComWebsite: https://www.Futuremarketinsights.ComLinkedInTwitterBlogsYouTube
Emerging Breakthroughs In Uveal Melanoma Treatment…
The Uveal Melanoma Treatment Market is anticipated to reach a value of US$ 1.4 billion in 2023 and US$ 2.4 billion by 2033. For the projection period, a CAGR of 5.5% is predicted for the market. The following are the variables driving rising demand for uveal melanoma.
FMI provides insights into market data on over 5000+ drugs from over 100 countries, which aids research on the current and upcoming market scenario for the Uveal melanoma Treatment market. Our healthcare experts track the data of established players as well as new entrants in the medical industry to provide unbiased analysis for a sound and financial decision.
Download Now: Explore the Booming Uveal Melanoma Treatment Market with Our Sample Report! @ https://www.Futuremarketinsights.Com/reports/sample/rep-gb-13010
Over the past decade, the healthcare sector has been expanding remarkably, following the advent of artificial Intelligence and the Internet of Things integrated medical devices. Advancement in technology has created impressive scope within the medical sector for diagnostics and therapeutics.
The report offers extensive data sets validating key trends impacting growth in the Uveal melanoma Treatment market. It offers insights into strategies adopted by the key players rise and addresses the concerns that will challenge the growth of Uveal melanoma Treatment market. With our extensive research and information about the past, current and future market scenario, the Uveal melanoma Treatment market report will help and identify the concerns, for a smooth sail of the small & medium as well as large enterprises.
Critical Questions Answered in the Report
The road to knowledge: Understanding the study's underlying assumptions. @ https://www.Futuremarketinsights.Com/ask-question/rep-gb-13010
Uveal melanoma Treatment Market: Segmentation
Based on diagnostic tests :
Based on therapy type :
Based on Location Type :
Based on Eye exams :
Based on end user :
Comprehensive analysis of the regional markets offers exclusive insights on the market performance across geographies along with relevant graphs, figures, and a list of tables.
Customize Your Report: Tailor the Exclusive Insights to Your Uveal Melanoma Treatment Market Strategy! Https://www.Futuremarketinsights.Com/customization-available/rep-gb-13010
Competitive Analysis
By Prominent Market Players
With an extensive SWOT analysis, the FMI's study presents the strengths, weaknesses, growth prospects and challenges of each player. The report also includes important data including the sales strategy, pricing strategy, and marketing strategy adopted by these players in the Uveal melanoma Treatment market
Explore Wide-ranging Coverage of FMI's Healthcare Landscape
Knee Replacement Market: The knee replacement market is anticipated to register a CAGR of 6% during the forecast period, up from US$ 8.27 Bn in 2021 to reach a valuation of US$ 15.7 Bn by 2032.
Digital Radiography Detectors Market: The digital radiography detectors market is valued at US$ 2.13 Bn in 2022. The market is advancing at an average pace with a CAGR of 6.1% through 2026 to reach a valuation of US$ 2.7 Bn.
Amniotic Membranes Market: The global amniotic membranes market size is likely to touch a valuation of around US$ 1.4 Bn in 2022. Further, with rising adoption of amniotic membranes for various purposes in ophthalmology, the total sales of amniotic membranes are slated to grow at an impressive CAGR of 9.0% between 2022 and 2028, totaling over US$ 2.3 Bn by the end of 2028.
About Future Market Insights (FMI)
Future Market Insights, Inc. (ESOMAR certified, Stevie Award – recipient market research organization and a member of Greater New York Chamber of Commerce) provides in-depth insights into governing factors elevating the demand in the market. It discloses opportunities that will favor the market growth in various segments on the basis of Source, Application, Sales Channel and End Use over the next 10-years.
Contact Us:
Future Market Insights Inc.Christiana Corporate, 200 Continental Drive,Suite 401, Newark, Delaware – 19713, USAT: +1-845-579-5705For Sales Enquiries: sales@futuremarketinsights.ComWebsite: https://www.Futuremarketinsights.ComLinkedInTwitterBlogsYouTube
Comments
Post a Comment